Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (1)
  • Closed (6)

Medical Condition

  • Show all (115)
  • Blood Disorders (2)
  • Cancer (19)
    • Leukemia (5)
    • Liver Cancer (1)
    • (-) Lymphoma (5)
    • Multiple Myeloma (4)
    • Skin Cancer (1)
  • COVID-19 (Coronavirus) (2)
  • Heart Disease (1)
  • Infectious Disease (5)
  • (-) Kidney Disease (2)
  • Liver Disease (18)
  • Pediatrics (15)
  • Transplant (51)
Displaying 1 - 7 of 7

Study of Isatuximab in Patients with Multiple Myeloma or Lymphoma who are Recovering from Stem Cell Transplant

Condition: Cancer / Lymphoma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant…
Read More

Study of Drug for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease

Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (like people who have had a transplant and must be on medications that suppress their immune system…
Read More

Study of MK-8228 (Letermovir) vs. Valganciclovir for Prevention of CMV Disease in Adult Kidney Transplant Recipients

Condition: Kidney Disease
Investigator: Marcus Pereira, MD, MPH
Status: Closed
The MK-8228-002 Study is studying the safety and effectiveness of an investigational medication for preventing cytomegalovirus (CMV) disease in adults with kidney transplants. The MK-8228-002 Study is evaluating an investigational medication (known as MK-8228) versus valganciclovir (VGCV). VGCV is an antiviral medication and…
Read More

HOPE in Action: Trial of HIV+ Deceased Donor Kidney Transplants for HIV+ Recipients

Condition: Kidney Disease
Investigator: Marcus Pereira, MD, MPH
Status: Closed
This research is being done to learn whether organ transplantation from HIV-positive deceased donors is as safe and effective in HIV-positive recipients as transplants from HIV-negative deceased donors. People with end-stage organ disease and HIV infection, and who qualify for organ…
Read More

Study for patients with Diffuse Large B-Cell Lymphoma (DLBCL) using stem cells

Condition: Cancer / Lymphoma
Investigator: Markus Mapara, MD
Status: Closed
The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant. An autologous transplant is infusion of your own bone marrow cells (stem cells) following a high-dose of chemotherapy. Autologous transplant is the standard…
Read More

Study of EBV-Cytotoxic T Lymphocytes (EBV-CTLs) in Patients with Epstein-Barr Virus-Associated Viremia or Malignancies

Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (people who have had a transplant and those who have immune disorders), EBV can cause certain…
Read More

Study of Tazemetostat or Zanubrutinib for Patients with Large B-Cell Lymphoma (LBCL)

Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large B-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier treatment. The addition of…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science